NCT03086239 - A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 28, 2017

Primary Completion Date

January 30, 2018

Study Completion Date

August 20, 2018

Conditions

Small Cell Lung Cancer

Interventions

DRUG

Rovalpituzumab tesirine

Intravenous

Trial Locations (5)

National Cancer Ctr Hosp East /ID# 161432, Kashiwa-shi

Kyushu University Hospital /ID# 161430, Fukuoka

Kinki University -Osakasayama Campus /ID# 161431, Osakasayama-shi

National Cancer Center Hospital /ID# 161429, Chuo-ku

Wakayama Medical University /ID# 161428, Wakayama